No products in the cart.
Oral semaglutide reduces cardiovascular event rates in high-risk patients
1. In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in patients with type...
Arsa-cel preserves motor and cognitive function in metachromatic leukodystrophy
1. In this prospective cohort study, treatment with atidarsagene autotemce (arsa-cel) significantly reduced the risk of severe motor impairment and death...
Hereditary erythrocytosis is associated with a fetal-like EPO isoform
1. This case series identified three non-coding erythropoietin (EPO) variants that significantly increased gene expression under hypoxic conditions. 2. The...
Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates
1. In concurrent randomized controlled trials (GEMINI 1 and GEMINI 2) of patients with relapsing multiple sclerosis (RMS), tolebrutinib did...
Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...
Genomic sequencing identifies variants linked to congenital diarrhea and enteropathies
1. In this cross-sectional study, nearly half of the infants with congenital diarrhea and enteropathies (CODEs) had identifiable causal variants,...
Safer Births Bundle of Care reduces perinatal mortality in Tanzania
1. In this prospective cohort study, implementation of the Safer Births Bundle of Care program was associated with a significant...
Male partner treatment lowers the risk of bacterial vaginosis reoccurrence
1. In this randomized controlled trial, female patients with bacterial vaginosis (BV) had lower recurrence rates when their male partner...
Infigratinib shows promising efficacy and tolerability in pediatric achondroplasia
1. In this phase two dose-finding study in children with achondroplasia, daily oral Infigratinib did not lead to any grade...
Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer
1. In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with residual human epidermal...